-Pablo Tebas Researcher Activity Profile

Research Author Detailed Information 

Pablo Tebas Publication Rate By Year

Pablo Tebas has published 2 paper(s) in 2006, 10 paper(s) in 2007, for a total of 12 research publications in total.

Pablo P Tebas Author Information

LAST NAME: tebas

FIRST NAME: pablo

INITIALS: P

AFFILIATION:

Papers

Pablo Tebas's Publication Record

1. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. Year Published: 2006
School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts, United States of America. foulkes@schoolph.umass.edu
2. Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. Year Published: 2006
Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH 44106, USA. MXL6@case.edu
3. Cardiovascular risks of antiretroviral therapies. Year Published: 2007
Washington University School of Medicine, Saint Louis, Missouri 63110, USA. kmondy@im.wustl.edu
4. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. Year Published: 2007
AIDS Clinical Research Unit (R-60A), Department of Medicine, University of Miami School of Medicine, 1800 NW 10th Avenue, Miami, FL 33136, USA. mfischl@med.miami.edu
5. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Year Published: 2007
Department of Internal Medicine, University of California-Los Angeles, USA.
6. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. Year Published: 2007
Center for Clinical AIDS Research and Education, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA. jscurrier@mednet.ucla.edu
7. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). Year Published: 2007
Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA. pablo.tebas@uphs.upenn.edu
8. Interventions for body habitus changes associated with HIV infection and its treatment. Year Published: 2007
University of Pennsylvania, AIDS Clinical Research Unit, 3451 Walnut Street, Philadelphia, PA 19104, USA. pablo.tebas@uphs.upenn.edu
9. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. Year Published: 2007
Division of Allergy and Immunology, Children's Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
10. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. Year Published: 2007
Rainbow Babies and Children's Hospital and Case Western Reserve University, Cleveland, Ohio, USA. gam9@case.edu
11. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. Year Published: 2007
Rainbow Babies and Children's Hospital and Case Western Reserve University, Cleveland, Ohio, USA. gam9@case.edu
12. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. Year Published: 2007
Rainbow Babies and Children's Hospital and Case Western Reserve University, Cleveland, Ohio, USA. gam9@case.edu